Table 3.

Mean and 95% confidence interval (95% CI) of total breast volume (TBV) (cm³), fibroglandular tissue volume (FGV), and FGV% in the soy and placebo groups at baseline and at the end of 12 months of intervention

Measure	Treatment	N	Baseline mean (95% CI)	P value between treatments at baseline	Month 12 mean (95% CI)	Ratio month 12 / baseline mean	P value-ratio within treatments	P value-ratio between treatments
All subjects
TBV	Soy	44	868.0 (725.9, 1022.7)	0.92	866.7 (722.5, 1024.0)	1.00 (0.97, 1.03)	0.57	0.65
	Placebo	41	826.9 (728.7, 931.3)		824.4 (722.8, 932.7)	0.99 (0.96, 1.03)	0.96
FGV	Soy	44	37.4 (26.7, 50.0)	0.033	35.2 (25.1, 47.0)	0.90 (0.78, 1.04)	0.14	0.74
	Placebo	41	52.9 (39.1, 68.8)		49.6 (36.4, 64.8)	0.91 (0.82, 1.01)	0.051
FGV%	Soy	44	4.8 (3.4, 6.6)	0.095	4.5 (3.2, 6.1)	0.90 (0.77, 1.06)	0.22	0.48
	Placebo	41	7.1 (5.0, 9.6)		6.6 (4.7, 8.8)	0.92 (0.82, 1.02)	0.056
Breast cancer patients
TBV	Soy	29	849.6 (672.2, 1047.8)	0.79	846.6 (664.3, 1051.0)	0.99 (0.95, 1.03)	0.33	0.47
	Placebo	29	844.4 (741.0, 954.6)		847.5 (737.5, 965.1)	1.00 (0.97, 1.03)	0.96
FGV	Soy	29	32.0 (22.4, 43.4)	0.13	28.6 (19.6, 39.4)	0.83 (0.67, 1.03)	0.028	0.69
	Placebo	29	45.0 (30.8, 61.9)		42.0 (28.4, 58.3)	0.90 (0.78, 1.03)	0.14
FGV%	Soy	29	4.3 (2.8, 6.1)	0.31	3.9 (2.5, 5.7)	0.84 (0.66, 1.06)	0.068	0.91
	Placebo	29	5.6 (3.8, 7.8)		5.1 (3.6, 6.9)	0.90 (0.78, 1.04)	0.11